Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Metrics to compare | TCRT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCRTPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.5x | −0.6x | |
PEG Ratio | 0.00 | 0.03 | 0.00 | |
Price / Book | 1.2x | 2.1x | 2.6x | |
Price / LTM Sales | 475.8x | 24.6x | 3.2x | |
Upside (Analyst Target) | - | 427.3% | 45.4% | |
Fair Value Upside | Unlock | 21.3% | 7.7% | Unlock |